Both IL-17 and IL-6 levels were increased within HNSCC tissues and plasma of HNSCC patients that received treatment with 1,25(OH)2D3 (Table 3; Figure 3 and Figure 4, left panels). The gene discussed is IL17A; the disease is head and neck squamous cell carcinoma.